Preface XVII


I feel honored to be the Associate Editor of *Key Leaders' Opinion on Novel Progress in Diagnosis and Treatment of Prostate Cancer*. It is a pleasure to write this preface and recommend this valuable book.

Prostate cancer (PCa) is one of the most prevalent malignant tumors worldwide and is the leading cause of cancer death in men in developed countries. The currently recognized risk factors for PCa involve genetics, age, and ethnicity. In addition, environmental changes and high-fat diets may also be important factors contributing to the annual increase in the incidence of PCa.

Thanks to the promotion of PCa screening methods represented by prostate specific antigen (PSA), the early detection rate of PCa has increased rapidly. As a typical highly heterogeneous tumor, PCa can produce considerable therapeutic responses to various treatment methods, including endocrine therapy, chemotherapy, radiotherapy, and surgery. Therefore, finding more effective and personalized treatments for PCa is essential for improving the survival outcomes of patients and enhancing the quality of life.

It is worth noting that, with the continuous in-depth research on the mechanism of tumor occurrence, and the near-constant breakthroughs occurring in the field of radiotherapy and drug research, comprehensive treatments have provided more survival benefits to patients with advanced PCa. Active surveillance has also played an important role in the treatment strategy of PCa. The progress of novel imaging examination methods has provided new technical support for urology experts to conduct active monitoring in a more scientific and rational manner. In the advanced concept of personalized diagnosis and treatment of PCa, the progress in tumor molecular biology will always be supported by a solid theoretical foundation. In recent years, the application of new technologies, such as gene sequencing, has played a critical role in promoting the selection of targets for precise diagnosis and treatment of PCa.

This book covers a wide range of knowledge and includes various topics. We believe this publication provides a valuable summary of new advances in the diagnosis and treatment of PCa. Finally, I want to once again sincerely thank the editorial board for their efforts in compiling this book.



Yang Gao, MD

Department of Radiology,
Jiangsu Cancer Hospital
& Jiangsu Institute of Cancer Research
& Affiliated Cancer Hospital of Nanjing Medical University,
Nanjing, China